<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549120</url>
  </required_header>
  <id_info>
    <org_study_id>MAB104954</org_study_id>
    <nct_id>NCT00549120</nct_id>
  </id_info>
  <brief_title>Optimising the Propranolol Block Model</brief_title>
  <official_title>A Study to Optimise the Propranolol Block Model for Assessment of the Pharmacological Activity of Bronchodilators in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimising the propranolol block model
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bronchodilatory effects of inhaled beta2 agonists and anti-muscarinic drugs are the
      mainstay of symptomatic treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
      A new approach is to combine both pharmacological approaches in a single molecule - ie a dual
      pharmacophore. It will be necessary to explore the relative contribution of the beta2 agonist
      versus anti-muscarinic bronchodilator properties of such a molecule. One way to do that is to
      block one of the components. Inhibition of beta2 agonist-mediated bronchodilatation by the
      non-selective beta-blocker propranolol is an established experimental method. Therefore this
      method may be useful in exploring the pharmacology of a dual pharmacophore.

      Published studies have generally looked at the effect of a single dose of propranolol on a
      beta2 agonist over a relatively short period of time (a few hours). There is a desire to
      develop long acting bronchodilators that require once daily dosing only. Thus any dual
      pharmacophore developed is likely to have 24 hour duration of action after a single dose.
      Therefore to use this method of beta blockade to inhibit beta2 agonist mediated
      bronchodilation, it is necessary to confirm a dosing regimen of propranolol that has
      acceptable tolerability and is effective in blocking the effects of a beta2 agonist over 24
      hours. That is the main purpose of this study.

      It is also important to confirm that the bronchodilator effect of an antimuscarinic is
      unaffected by beta blockade. In addition, it is of interest to examine the bronchodilator
      effect of a combination of an antimuscarinic and beta2 agonist in healthy volunteers and the
      effect of propranolol on the combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2007</start_date>
  <completion_date type="Actual">October 26, 2007</completion_date>
  <primary_completion_date type="Actual">October 26, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific airway conductance (sGAW)</measure>
    <time_frame>Pre-dose and up to 26 h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability: adverse events, 12 lead ECG, blood pressure and heart rate</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Propranolol pharmacokinetics</measure>
    <time_frame>Pre-dose and up to 28 h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Propranolol alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol 80 mg (5 doses at 6 hourly intervals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol + salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (5 doses at 6 hourly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol + ipratropium + salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + ipratropium + salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>40 mg tablets</description>
    <arm_group_label>Propranolol + salbutamol</arm_group_label>
    <arm_group_label>Propranolol + ipratropium + salbutamol</arm_group_label>
    <arm_group_label>Propranolol alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Metered dose inhaler (600 μg)</description>
    <arm_group_label>Propranolol + salbutamol</arm_group_label>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Placebo + ipratropium + salbutamol</arm_group_label>
    <arm_group_label>Propranolol + ipratropium + salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium</intervention_name>
    <description>Metered dose inhaler (40 μg)</description>
    <arm_group_label>Placebo + ipratropium + salbutamol</arm_group_label>
    <arm_group_label>Propranolol + ipratropium + salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for propranolol tablets</description>
    <arm_group_label>Salbutamol alone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo + ipratropium + salbutamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or female aged between 18 and 50 years.

          -  Body mass index within the range 19-29.9 kilograms/metre2

          -  Forced Expiratory Volume in 1 second (FEV1) &gt;80% predicted and a FEV1/ Forced Vital
             Capacity (FVC) ratio &gt; 0.7

          -  The subject has an increase in sGAW of &gt;% over pre-dose baseline within 2 h of
             administration of 400 ug salbutamol by MDI inhaler at screening or in the 3 months
             before screening.

          -  Subject has an increase in sGaw of 25% over pre-dose baseline within 2 h following 40
             ug ipratropium bromide at screening or in the 3 months before screening

          -  Subjects are current non-smokers who have not used any tobacco products in the 6-month
             period preceding the screening visit and have a pack history of &lt; 10 pack years.

        Exclusion criteria:

          -  A past or present disease, which as judged by the Investigator and medical monitor may
             affect the outcome of the study or the safety of the subject

          -  History of respiratory disease

          -  Significant abnormal 12 lead ECG, QTc(B) and QTc(F) value at screening &gt;450msec on an
             individual ECG or a PR interval outside the range 120-210 msec

          -  Supine mean heart rate outside the range 45-90 beats per minute (bpm) at screening

          -  Subject has donated a unit of blood within the 56 days or intends to donate within 56
             days after completing the study

          -  Subject is currently taking regular (or course of) medication whether prescribed or
             not (with the exception of contraceptives, including vitamins and herbal remedies such
             as St John's Wort)

          -  Subject has participated in a clinical study with a New Chemical Entity (NCE) within
             the past 1 month

          -  Infected with the Hepatitis B, Hepatitis C, or HIV virus

          -  Subject has a history of drug or other allergy, which, in the opinion of the
             Investigator, contraindicates their participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/MAB104954?search=study&amp;search_terms=104954#rs</url>
    <description>Results for study MAB104954 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <keyword>muscarinic receptor antagonist</keyword>
  <keyword>propranolol</keyword>
  <keyword>beta-blocker</keyword>
  <keyword>beta-agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MAB104954</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

